Munich Cancer Registry

- Incidence and Mortality
- Selection Matrix
- Homepage
- *Deutsch*

ICD-10 C49: Soft tissue cancer

Survival

Year of diagnosis	1988-1997	1998-2020
Patients	468	2,863
Diseases	468	2,876
Cases evaluated	428	2,140

Creation date	04/15/2022
Database export	12/20/2021
Population	4.92 m

Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninistr. 15
Munich, 81377
Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC49__E-ICD-10-C49-Soft-tissue-cancer-survival.pdf

Index of figures and tables



Figure 1a. Relative survival of patients with soft tissue cancer by period of diagnosis. Included in the evaluation are 2,541 cases diagnosed between 1988 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2018, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	Period of diagnosis							
	1988-1997 n=425		1998-2006 n=733		2007-2015 n=1,027		2016+ n=356	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	81.9	83.7	83.7	85.6	81.1	83.2	82.0	83.8
2	71.5	74.3	74.3	77.5	71.6	75.1	73.0	76.1
3	64.5	68.2	67.3	71.6	65.6	70.2	65.9	70.4
4	58.4	62.9	62.6	67.8	61.6	67.2	62.6	68.3
5	54.7	59.9	59.0	65.2	58.8	65.4		
6	51.5	57.3	56.0	62.9	55.5	62.9		
7	48.8	55.1	53.8	61.5	53.9	62.3		
8	46.2	53.2	51.1	59.6	52.0	61.1		
9	45.0	52.5	48.8	58.1	50.2	60.1		
10	42.7	50.9	47.1	57.0	48.1	58.7		
11	40.4	49.0	46.5	57.3	47.9	59.4		
12	38.8	47.8	44.9	56.5	45.8	57.9		
13	37.7	47.2	43.0	55.1	43.7	56.1		
14	36.6	46.6	41.7	54.5	40.2	50.8		
15	34.5	44.8	40.6	54.0				
Median	6.4		8.4		9.1			

Table 1b. Observed (obs.) and relative (rel.) survival of patients with soft tissue cancer by period of diagnosis for period 1988-2020 (N=2,541).



Figure 2a. Survival of patients with soft tissue cancer by sex. Included in the evaluation are 2,116 cases diagnosed between 1998 and 2020.

	Sex			
	Male n=1,131		Female n=985	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	81.2	83.5	83.2	85.0
2	72.4	76.2	73.2	76.1
3	66.6	71.7	65.9	69.7
4	63.1	69.5	60.9	65.3
5	59.8	67.3	58.0	63.2
6	55.6	63.9	56.1	62.0
7	53.5	62.9	54.4	61.1
8	50.7	60.9	52.7	60.2
9	49.3	60.4	49.9	58.1
10	47.7	59.5	47.7	56.4
11	47.1	59.9	47.5	56.9
12	44.5	58.0	46.6	56.7
13	41.9	55.8	45.3	56.2
14	40.3	54.9	43.8	55.1
15	38.3	53.1	42.7	55.0
Median	8.5		9.0	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with soft tissue cancer by sex for period 1998-2020 (N=2,116).



Figure 3a. Relative survival of patients with soft tissue cancer by age category. Included in the evaluation are 2,116 cases diagnosed between 1998 and 2020.

	Age category									
	0-49 yrs n=616		50-59 yrs n=312		60-69 yrs n=444		70-79 yrs n=434		80+ yrs n=310	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	91.0	91.1	90.5	91.0	83.7	84.7	77.9	80.2	59.8	66.4
2	84.2	84.4	83.8	84.6	73.7	75.6	67.1	71.3	46.0	56.9
3	79.0	79.1	80.6	82.0	66.4	69.1	60.0	66.3	35.6	49.4
4	76.1	76.3	76.5	78.3	63.4	67.0	54.4	62.4	29.0	45.4
5	73.5	73.8	72.3	74.3	60.7	65.2	51.8	62.0	24.5	44.1
6	72.0	72.5	68.2	70.9	57.9	63.2	47.7	59.9	19.4	40.2
7	70.6	71.1	67.0	70.1	56.1	62.4	44.7	59.4	17.2	41.1
8	69.5	70.1	65.2	68.8	54.2	61.6	41.7	58.6	12.4	34.4
9	68.9	69.7	63.7	68.1	51.8	60.4	38.0	57.2		
10	68.9	69.7	62.0	67.1	49.9	59.3	33.5	54.3		
11	68.6	69.6	62.0	67.6	48.7	59.6	33.0	57.8		
12	68.3	69.4	62.0	68.0	45.6	57.4	28.3	55.0		
13	67.8	68.9	59.6	66.9	43.1	56.3	23.7	50.7		
14	66.9	68.4	58.5	66.9	41.9	56.3	21.2	50.3		
15	66.9	68.1	57.3	66.4	40.5	56.8	17.5	47.5		
Median					9.9		5.7		1.5	

Table 3b. Observed (obs.) and relative (rel.) survival of patients with soft tissue cancer by age category for period 1998-2020 (N=2,116).



Figure 4a. Relative survival of patients with soft tissue cancer by extent of disease. For 1,379 of 2,116 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 1,336 cases an evaluable classification was established. The grey line represents the subgroup of 780 patients with missing values regarding extent of disease (36.9 % of 2,116 patients, the percent values of all other categories are related to n=1,336).

	Extent of disease							
	Local n=1,044		Regional n=44		Distant n=248		NA/NOS n=780	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	92.3	94.2	62.9	62.4	48.0	49.0	80.4	83.0
2	83.7	87.0			32.1	33.2	72.6	76.9
3	77.4	82.0			21.3	22.3	66.9	72.7
4	72.8	78.5			19.0	19.5	62.4	69.4
5	69.5	76.2			15.8	16.3	59.5	67.7
6	65.5	73.1			14.5	15.3	56.7	65.8
7	63.4	71.9					54.7	64.8
8	59.8	69.0					53.3	64.6
9	56.8	66.7					51.9	64.4
10	55.3	65.8					49.2	62.3
Median	13.1		1.7		1.0		9.9	

Table 4b. Observed (obs.) and relative (rel.) survival of patients with soft tissue cancer by extent of disease for period 1998-2020 (N=1,336).



Figure 4c. Conditional relative 2-year survival of patients with soft tissue cancer by extent of disease. For 1,379 of 2,116 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 1,336 cases an evaluable classification was established. The grey line represents the subgroup of 780 patients with missing values regarding extent of disease (36.9 % of 2,116 patients, the percent values of all other categories are related to n=1,336).

	Extent of disease							
	Local		Regional		Distant		NA/NOS	
Years	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs	n	Cond. surv. % 2 yrs
0	1,044	87.0	44		248	33.2	780	76.9
1	929	87.2			112	45.4	608	87.7
2	797	90.4			72	58.6	537	90.6
3	692	93.3			42	73.1	481	93.7
4	612	93.5			33	76.2	438	95.7
5	552	94.9					404	96.8

Table 4d. Conditional relative 2-year survival of patients with soft tissue cancer by extent of disease for period 1998-2020 (N=1,336).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 4a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease=“Local”, who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 93.3% (n=692).



Figure 5a. Time to first progression of 2,104 patients with soft tissue cancer diagnosed between 1998 and 2020 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

	Type of progression						
	Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	Distant metastasis (CI)
N	1,863	1,863	2,104	2,104	2,104	2,104	1,863
Events	880	880	361	361	54	54	452
compet.	223		824		994		454
Years	%	%	%	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	25.3	25.8	6.6	7.4	1.0	1.2	9.4
2	35.2	36.1	10.5	12.4	1.6	1.9	16.3
3	39.9	41.1	13.2	16.2	2.0	2.4	20.0
4	42.7	44.1	14.8	18.4	2.0	2.4	21.5
5	45.2	46.9	15.9	20.2	2.3	3.0	23.3
6	46.5	48.4	16.6	21.3	2.4	3.1	24.3
7	47.4	49.3	17.0	22.0	2.5	3.4	25.1
8	47.9	50.0	17.5	22.9	2.6	3.5	25.4
9	48.8	51.0	18.1	23.8	2.8	3.8	25.6
10	49.5	51.8	18.6	24.8	2.8	3.8	26.1
11	49.9	52.3	18.8	25.2	2.8	3.8	26.1
12	50.1	52.6	18.9	25.4	2.8	4.0	26.2
13	50.5	53.1	19.1	25.8	2.8	4.0	26.3
14	50.9	53.7	19.1	25.8	3.0	4.3	26.5
15	51.3	54.2	19.3	26.2	3.0	4.3	26.8

	Type of progression		
cont'd	Distant metast. (1-KM)	NOS (CI)	NOS (1-KM)
N	1,863	2,104	2,104
Events	452	316	316
compet.		811	
Years	%	%	%
0	0.0	0.0	0.0
1	10.0	10.3	11.0
2	17.7	12.8	14.0
3	22.0	13.4	14.9
4	23.8	14.1	15.8
5	26.0	14.3	16.2
6	27.2	14.6	16.6
7	28.2	14.9	17.1
8	28.7	14.9	17.1
9	28.9	15.2	17.5
10	29.6	15.3	17.8
11	29.6	15.6	18.4
12	29.8	15.7	18.6
13	30.0	15.9	19.0
14	30.2	16.4	19.9
15	30.8	16.4	19.9

Table 5b. Time to first progression of patients with soft tissue cancer for period 1998-2020 (N=2,104), also showing the total of progression events (Events) and of deaths as competing risk (compet.).



Figure 5c. Observed post-progression survival of 916 patients with soft tissue cancer diagnosed between 1998 and 2020. These 916 patients with documented progression events during their course of disease represent 43.5 % of the totally 2,104 evaluated cases (incl. M1, n=241, 11.5 %). Patients with cancer relapse documented via death certificates only were excluded (n=212, 10.1 %). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potientially considered in more than one subgroup.

	Type of progression				
	Any type	Local relapse	Lymph node	Distant metastasis	NOS
	n=916	n=366	n=53	n=560	n=201
Years	%	%	%	%	%
0	100.0	100.0	100.0	100.0	100.0
1	66.1	74.6	53.3	52.0	72.5
2	50.1	58.7		34.2	60.5
3	41.3	52.4		23.7	54.3
4	36.4	46.5		19.2	49.0
5	32.8	42.2		14.8	47.6
6	30.3	40.1		13.6	43.3
7	28.3	36.2		12.9	41.1
8	27.3	35.7		12.1	39.5
9	26.0	34.0		11.3	37.7
10	25.2	32.2		11.3	37.7

Table 5d. Observed post-progression survival of patients with soft tissue cancer for period 1998-2020 (N=916).



Figure 5e. Observed post-progression (distant metastasis) survival of 685 patients with soft tissue cancer diagnosed between 1988 and 2020 by period of progression.

	Period of progression			
	1988-1997 n=90	1998-2006 n=171	2007-2015 n=272	2016+ n=152
Years	%	%	%	%
0	100.0	100.0	100.0	100.0
1	55.1	48.5	51.3	60.8
2	33.7	28.8	33.1	46.1
3	23.6	17.7	23.3	35.4
4			20.3	
5			15.8	
6			14.2	
7			13.4	
8			12.0	
9			11.4	

Table 5f. Observed post-progression (distant metastasis) survival of patients with soft tissue cancer for period 1988-2020 by period of progression (N=685).

Shortcuts

MCR	Munich Cancer Registry, Germany	
NCI	National Cancer Institute, USA	
SEER	Surveillance, Epidemiology, and End Results, USA	
UICC	Union for International Cancer Control, Geneva	
DCO	Death certificate only	Death certificate provides the only notification to the registry.
NA	Not available	
NOS	Not otherwise specified	
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause
RS	Relative survival	Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival
AS	Assembled survival	Assembled chart of observed, expected, relative survival
CS	Conditional survival	Survival probability under the condition of surviving a given period of time
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
	1-KM	1 minus Kaplan-Meier estimator (“inverse” Kaplan-Meier estimator)
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C49: Soft tissue cancer [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregister-muenchen.de/en/facts/surv/sC49__E-ICD-10-C49-Soft-tissue-cancer-survival.pdf

Copyright

Disclaimer